Argent BioPharma (ASX:RGT) is advancing the expansion of its CannEpil® platform into the U.S. veterinary healthcare market, with its exclusive licensing partner commencing a development programme focused initially on companion-animal oncology and chronic pain management.
🐾 U.S. veterinary programme: Splash Beverage Group has commenced development of CannEpil® for veterinary applications through a collaboration with Lupvindol Biosciences, marking the first operational milestone since the product’s expansion into animal healthcare.
🧬 U.S. FDA pathway: The programme will initially target canine applications and progress through the U.S. FDA Center for Veterinary Medicine, beginning with the Investigational New Animal Drug process and potentially advancing towards Conditional Approval.
🇺🇸 Experienced team: Lupvindol Biosciences CEO Dr. Hunter Land, a former GW Pharmaceuticals executive involved in the development of Epidiolex® and Sativex®, will lead pharmaceutical development and regulatory strategy. Argent BioPharma retains ownership of CannEpil® intellectual property and manufacturing know-how, while participating through royalties.

"This milestone demonstrates that the global licensing strategy is already translating into tangible operational progress." – Roby Zomer, Argent BioPharma Chairman

Elk Range Mining has listed on the ASX with the ticker code of ELK. The company is a mineral explorer that owns a high-quality portfolio of gold assets located in the US state of Idaho. Its flagship asset is the Friday Gold Mine, which is positioned within one of the US’s most prospective and historically productive gold districts. Elk Range Mining also owns the Orogrande Processing Plant and associated infrastructure, which provides the Company with strategic and commercial optionality as its development strategy is delivered. Proceeds from the IPO raise will support Elk Range Mining’s planned exploration and development activities, including resource growth drilling, technical studies and permitting.

Media: The Stock Network, Lel Smits

Every ETF tracks something, but many investors spend more time researching the ETF than understanding the asset market benchmark or index it follows. These indices, which include stock market benchmarks, play a critical role in determining an ETF`s holdings, performance characteristics and investment outcomes, making them one of the most important yet often overlooked components of ETF investing. In this Women in ETFs ETF Education Spotlight, The Stock Network`s Lel Smits is joined by Daphne van der Oord, Head of Australia & New Zealand at S&P Dow Jones Indices, to discuss what asset market benchmarks or indices are, why they matter, and how investors can better understand what`s driving the ETFs they own.

📊 What is a benchmark index?
📈 How asset market indices shape ETFs
🔍 Not all indices are created equal
💻 Why investors should look beyond fees
🎯 Choosing the right benchmark index

Clean TeQ Water (ASX:CNQ) completes commissioning and performance testing of its first full-scale commercial PHOSPHIX® phosphate removal plant in Europe, marking a key commercial milestone for the company`s water treatment technology.

💧 Commercial milestone: The PHOSPHIX® plant, delivered with Enva in Ireland, becomes Clean TeQ Water`s first commercial operating reference in Europe following its successful commissioning and testing.
✅ Performance exceeds targets: Independent laboratory testing showed phosphate concentrations below 0.1 mg/L, exceeding the contractual requirement of 1.0 mg/L by more than tenfold, while the plant also operated above its designed hydraulic capacity.
🌍 Growth platform: The successful deployment provides a commercial reference plant for prospective customers and strengthens Clean TeQ Water`s position to pursue new industrial and municipal phosphate removal opportunities across Europe as environmental regulations tighten.

"Today`s announcement marks the successful commercial deployment of PHOSPHIX® at full industrial scale, consistently delivering phosphate concentrations well below contractual requirements while exceeding design throughput." – Peter Voigt, CEO

SciDev (ASX:SDV) secures its first revenue-generating contracts in the data centre market, marking a strategic expansion into a new growth sector. The contracts involve engineering and consulting work for two of Australia`s largest hyperscale data centre operators and developers.

💧 New market entry: SciDev has won its first contracts in the data centre sector, providing design, consulting and embedded engineering services for two major Australian hyperscale data centre operators and developers.
📈 Revenue opportunity: The contracts are expected to generate approximately $0.5 million in revenue during the first half of FY27, with potential for the scope and duration of services to expand over time.
⚙️ Growth platform: These initial data centre sector-related contracts provide valuable reference work in a market SciDev has identified as a strategic growth priority, and leverage the company’s expertise in water recycling, reuse and advanced treatment solutions for increasingly water-intensive data centres.

"Securing our first revenue-generating contracts in the data centre market is an important early step in validating SciDev`s strategy to build a differentiated position in this emerging sector." – SciDev CEO Todd Scott

Which American shares returned 44 per cent over the last year? Not the ones you might think. The Russell 2000 is the index of America’s smallest two thousand small companies within the Russell 3000 Index. Large caps, measured by the Russell 1000, returned about 30 per cent. Small caps, measured by the Russell 2000, returned more than 44%

So why did the small companies surge? Firstly, interest rates, small caps carry far more floating-rate debt and when rates fell their borrowing costs dropped too. Second, valuations - US small caps were trading at just 16 times forecast earnings, while large caps were at 23. Finally, the AI boom expanded, data centres need power, cooling, networking, construction, and a lot of that gets built by companies you`ve never heard of in the Russell 2000.

#stocks #wallstreet #US #money #investing

Control Bionics (ASX:CBL) reports commercial progress across its Assistive Technology and NeuroTechnology Solutions businesses, with expanding distribution channels and growing adoption of its NeuroStrip™ platform.

🧠 Commercial growth: The company shipped its first NextLevel tablets, expanded US distribution through Tobii Dynavox and PRC-Saltillo, and expects to appoint its first German distribution partner in the coming weeks.
🌍 NeuroStrip™ adoption: NeuroStrip™ has now signed 20 organisations across four countries, spanning elite sport, rehabilitation, clinical and research settings.
📊 Clinical validation: An interim report from Japan`s STROKE LAB supports NeuroStrip™ as an objective assessment tool capable of measuring muscle activity beyond conventional rehabilitation assessments. The findings are interim, observational and do not establish therapeutic efficacy.

“That is the clearest evidence yet that our strategic shift to a multi-application neurotechnology platform is working.” – Jeremy Steele, Control Bionics CEO & Managing Director

Pepper Money (ASX:PPM) expands its capital-light servicing business after being appointed as servicer of a A$36 billion home loan and personal loan portfolio originated by HSBC Australia following the proposed acquisition of these assets by funds managed by affiliates of Blackstone.

🏦 Major servicing mandate: Pepper Money will service approximately A$36 billion of Australian home loans and personal loans once the proposed acquisition of these loans by the Blackstone-controlled purchaser completes.
📈 Recurring revenue: The appointment supports Pepper Money`s strategy to grow its capital-light servicing business, increasing recurring, annuity-style earnings while expanding operational scale.
⏳ Targeted completion date: The transaction is subject to regulatory approvals and operational readiness, with completion expected in the first half of calendar 2027.